Suppr超能文献

免疫系统塑造的从导管原位癌到浸润性导管乳腺癌的基因组改变。

Genomic Alterations during the to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System.

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

Mol Cancer Res. 2021 Apr;19(4):623-635. doi: 10.1158/1541-7786.MCR-20-0949. Epub 2020 Dec 18.

Abstract

The drivers of ductal carcinoma (DCIS) to invasive ductal carcinoma (IDC) transition are poorly understood. Here, we conducted an integrated genomic, transcriptomic, and whole-slide image analysis to evaluate changes in copy-number profiles, mutational profiles, expression, neoantigen load, and topology in 6 cases of matched pure DCIS and recurrent IDC. We demonstrate through combined copy-number and mutational analysis that recurrent IDC can be genetically related to its pure DCIS despite long latency periods and therapeutic interventions. Immune "hot" and "cold" tumors can arise as early as DCIS and are subtype-specific. Topologic analysis showed a similar degree of pan-leukocyte-tumor mixing in both DCIS and IDC but differ when assessing specific immune subpopulations such as CD4 T cells and CD68 macrophages. Tumor-specific copy-number aberrations in MHC-I presentation machinery and losses in 3p, 4q, and 5p are associated with differences in immune signaling in estrogen receptor (ER)-negative IDC. Common oncogenic hotspot mutations in genes including and are predicted to be neoantigens yet are paradoxically conserved during the DCIS-to-IDC transition, and are associated with differences in immune signaling. We highlight both tumor and immune-specific changes in the transition of pure DCIS to IDC, including genetic changes in tumor cells that may have a role in modulating immune function and assist in immune escape, driving the transition to IDC. IMPLICATIONS: We demonstrate that the to IDC evolutionary bottleneck is shaped by both tumor and immune cells.

摘要

导管癌(DCIS)向浸润性导管癌(IDC)转变的驱动因素尚不清楚。在这里,我们进行了综合基因组、转录组和全切片图像分析,以评估 6 例匹配的纯 DCIS 和复发性 IDC 中拷贝数谱、突变谱、表达、新抗原负荷和拓扑结构的变化。我们通过联合拷贝数和突变分析表明,尽管潜伏时间长且经过治疗干预,复发性 IDC 仍可与其纯 DCIS 在遗传上相关。免疫“热”和“冷”肿瘤早在 DCIS 时就可能出现,并且具有亚型特异性。拓扑分析显示,DCIS 和 IDC 中均存在相同程度的全白细胞-肿瘤混合,但在评估特定免疫亚群(如 CD4 T 细胞和 CD68 巨噬细胞)时则不同。MHC-I 呈递机制中的肿瘤特异性拷贝数异常和 3p、4q 和 5p 的缺失与雌激素受体(ER)阴性 IDC 中的免疫信号差异相关。包括 和 在内的基因中的常见致癌热点突变被预测为新抗原,但在 DCIS 向 IDC 转变过程中却被保守,并且与免疫信号差异相关。我们强调了从纯 DCIS 向 IDC 转变过程中肿瘤和免疫的特异性变化,包括肿瘤细胞中的遗传变化,这些变化可能在调节免疫功能和协助免疫逃逸方面发挥作用,从而推动向 IDC 的转变。意义:我们证明,到 IDC 的进化瓶颈是由肿瘤细胞和免疫细胞共同塑造的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52df/8026652/adea55f2cee1/nihms-1656558-f0001.jpg

相似文献

3
Immune Escape in Breast Cancer During to Invasive Carcinoma Transition.乳腺癌从原位癌向浸润性癌转变过程中的免疫逃逸
Cancer Discov. 2017 Oct;7(10):1098-1115. doi: 10.1158/2159-8290.CD-17-0222. Epub 2017 Jun 26.

引用本文的文献

3
Molecular Basis of Breast Tumor Heterogeneity.乳腺肿瘤异质性的分子基础
Adv Exp Med Biol. 2025;1464:237-257. doi: 10.1007/978-3-031-70875-6_13.

本文引用的文献

1
Immune Escape during Breast Tumor Progression.在乳腺癌进展过程中的免疫逃逸。
Cancer Immunol Res. 2020 Apr;8(4):422-427. doi: 10.1158/2326-6066.CIR-19-0786.
9
Neoantigen-directed immune escape in lung cancer evolution.肺癌进化中的新抗原定向免疫逃逸。
Nature. 2019 Mar;567(7749):479-485. doi: 10.1038/s41586-019-1032-7. Epub 2019 Mar 20.
10
The Immune Epitope Database (IEDB): 2018 update.免疫表位数据库(IEDB):2018 年更新。
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343. doi: 10.1093/nar/gky1006.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验